Prototype vaccine protects monkeys from coronavirus

A prototype vaccine has protected monkeys from the coronavirus, researchers reported Wednesday, a finding that offers new hope for effective human vaccines.

Scientists are testing coronavirus vaccines in people, but the initial trials are designed to determine safety, not how well a vaccine works. The research published Wednesday offers insight into what a vaccine must do to be effective and how to measure that.

“To me, this is convincing that a vaccine is possible,” said Dr. Nelson Michael, director of the Center for Infectious Diseases Research at Walter Reed Army Institute of Research.

Dr. Dan Barouch, a virologist at Beth Israel Deaconess Medical Center in Boston, and his colleagues have started a series of experiments on monkeys to get a broader look at how coronaviruses affect monkeys and whether vaccines might fight the pathogens. Their report was published in Science. Barouch is working in a partnership with Johnson & Johnson, which is developing a coronavirus vaccine that uses a specially modified virus that he developed, called Ad26.

In March, the federal government awarded $450 million to Janssen Pharmaceuticals, a division of Johnson & Johnson, to develop a coronavirus vaccine.

The scientists started by studying whether the monkeys become immune to the virus after getting sick. The team infected nine unvaccinated rhesus macaques with the new coronavirus.

The monkeys recovered after a few days, and Barouch and his colleagues found that the animals had begun making antibodies to the coronavirus. Some turned out to be so-called neutralizing antibodies, meaning that they stopped the virus from entering cells and reproducing.

Five weeks after inoculating the monkeys, the researchers sprayed a second dose of the coronavirus into the noses of the animals.

The monkeys produced a surge of protective neutralizing antibodies. The coronavirus briefly managed to establish a small infection in the monkeys’ noses but was soon wiped out.